Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 1,610 Shares

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 1,610 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $87,873.80. Following the completion of the sale, the chief operating officer now owns 40,555 shares of the company’s stock, valued at approximately $2,213,491.90. The trade was a 3.82 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Disc Medicine Stock Performance

Disc Medicine stock traded down $0.11 during midday trading on Thursday, hitting $54.35. 369,811 shares of the company’s stock were exchanged, compared to its average volume of 402,546. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -13.66 and a beta of 0.73. The firm’s 50 day simple moving average is $59.46 and its 200 day simple moving average is $55.02.

Analysts Set New Price Targets

A number of analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Wedbush reaffirmed an “outperform” rating and set a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Jefferies Financial Group started coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 target price on the stock. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Finally, Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a report on Tuesday, November 5th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $88.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IRON. Sterling Capital Management LLC boosted its holdings in shares of Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after acquiring an additional 503 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Disc Medicine in the fourth quarter valued at about $40,000. Tower Research Capital LLC TRC boosted its holdings in shares of Disc Medicine by 47.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after acquiring an additional 266 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in shares of Disc Medicine in the third quarter valued at about $131,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.